# Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

> **NCT03960957** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 301 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **BIOLOGICAL:** AbobotulinumtoxinA
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03960957
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2019-09-27
- **Final completion:** 2020-04-16
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960957, "Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03960957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*